Literature DB >> 17654320

Urotensin-II immunoreactivity in children with chronic glomerulonephritis.

Ayse Balat1, Metin Karakök, Kutluhan Yilmaz, Yasemin Kibar.   

Abstract

BACKGROUND: Human urotensin-II (hU-II) is one of the most potent vasoconstrictors in mammals. To our knowledge, there is no study about the role of U-II in childhood glomerulonephritis. We first determined the expression of h U-II in kidneys of children with chronic glomerular diseases.
METHODS: Normal human kidneys were obtained from postmortem biopsies and compared with the kidney biopsy specimens of 24 children with membranoproliferative glomerulonephritis (MPGN) and 6 children with membranous GN. Kidney needle biopsies in 10% neutral buffered-formalin prior to routine processing through to embedded blocking sections were cut, and immunohistochemical reactions were performed on paraffin-embedded tissue by an avidin-biotin peroxidase complex method. The antibodies used in the present study were hU-II. The positivities were revealed as weak (+), moderate (++), and severe (+++), according to the color intensity.
RESULTS: In kidneys of children with MPGN, differently fom the normal kidneys, more dense U-II immunoreactivity was seen in the glomerular basement membrane (GBM), glomerular mesangium, Bowman capsule, and tubules. Interestingly, we also observed U-II immunoreactivity in crescents. In children with MGN, U-II was mostly seen in GBM and Bowman capsule.
CONCLUSION: Our findings suggest that U-II may have a possible autocrine/paracrine function in the kidneys, and may be an important target molecule in studying renal pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654320     DOI: 10.1080/08860220701392108

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  9 in total

1.  Kidney is in trouble with mediators.

Authors:  Ayse Balat
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

2.  Effects of urotensin-II on cytokines in early acute liver failure in mice.

Authors:  Liang-Ming Liu; Liang Zhao; Dong-Yu Liang; Fang-Ping Yu; Chang-Gen Ye; Wen-Juan Tu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

3.  Loss of urotensin II receptor diminishes hyperglycemia and kidney injury in streptozotocin-treated mice.

Authors:  Dieniffer Peixoto-Neves; Praghalathan Kanthakumar; Ravi Kumar; Hitesh Soni; Adebowale Adebiyi
Journal:  J Mol Endocrinol       Date:  2022-03-25       Impact factor: 4.869

4.  Urotensin II-induced store-operated Ca2+ entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions.

Authors:  Hitesh Soni; Adebowale Adebiyi
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

5.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

6.  Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat.

Authors:  Heather J Eyre; Thomas Speight; Jocelyn D Glazier; David M Smith; Nick Ashton
Journal:  Exp Physiol       Date:  2019-01-15       Impact factor: 2.969

7.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10

Review 8.  Accessory proteins for heterotrimeric G-proteins in the kidney.

Authors:  Frank Park
Journal:  Front Physiol       Date:  2015-08-07       Impact factor: 4.566

9.  IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.

Authors:  Liang-Ming Liu; Wen-Juan Tu; Tong Zhu; Xiao-Ting Wang; Zhi-Li Tan; Huan Zhong; De-Yong Gao; Dong-Yu Liang
Journal:  Oncotarget       Date:  2016-08-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.